Lexicon Pharmaceuticals, Inc. (LXRX) SEC Filings & Earnings Calls

Revenue concentration risk: near-total reliance on licensing revenue from Novo Nordisk which did not recur in Q2 2026.

“Revenue dropped from $28.9M (including $27.6M licensing) to $0.7M.”

Clinical trial risk: SONATA-HCM and ZYNQUISTA NDA resubmission may fail or be delayed.

“Topline data expected Q1 2027; NDA resubmission in Q4 2026.”

Cash burn risk: net loss of $31.8M per quarter with minimal revenue.

“Net loss of $31.8 million; no cash balance disclosed.”

Revenue concentration on milestone payments

“Revenues for the six months ended June 30, 2026 included $20.0 million in development milestone revenue recognized from the Novo Nordisk licensing agreement.” · word for word

Accumulated deficit and ongoing losses

“Since our inception, we have incurred significant losses and, as of June 30, 2026, we had an accumulated deficit of approximately $2.1 billion.” · word for word

Concentrated ownership risk

“Artal Participations S.a r.l. is the record and beneficial owner of 175,156,062 shares of Issuer Common Stock, representing approximately 39.4% of the outstanding shares of Issuer Common Stock.” · word for word

Concentrated ownership risk

“Artal Participations S.a r.l. is the record and beneficial owner of 175,156,062 shares of Issuer Common Stock, representing approximately 39.4% of the outstanding shares of Issuer Common Stock.” · word for word

Dependence on pipeline success and regulatory approvals.

“SONATA-HCM and ZYNQUISTA NDA resubmission are key milestones.”

Cash burn risk despite loan facility.

“No revenue disclosed; net loss expected.”

Revenue concentration on milestone payments

“Revenues for the three months ended March 31, 2026 included $20.0 million in development milestone revenue recognized from the Novo Nordisk licensing agreement.” · word for word

Accumulated deficit and ongoing losses

“Since our inception, we have incurred significant losses and, as of March 31, 2026, we had an accumulated deficit of approximately $2.0 billion.” · word for word

Increased leverage risk: $100M debt with floating rate and covenants.

“Interest rate prime+3.10% (floor 9.85%); financial covenants include minimum cash and revenue.”

Dilution risk from warrants: up to 1.26M shares potentially issued.

“Warrants for 691,823 shares initially; additional warrants upon future tranches.”

Performance milestone risk: failure to meet HCM trial endpoints could trigger default or limit access to additional tranches.

“Interest-only period extension and second tranche availability depend on HCM trial success.”

Massive dilution: 20.4M new shares issued; authorized shares doubled.

“20,421,735 shares issued; authorized shares increased to 900M.”

Potential further dilution from equity plans: up to 90M shares available for issuance.

“2026 Equity Incentive Plan reserve increased to 90M shares.”

Shareholder dilution risk from authorized share increase

“increasing the number of authorized shares of our common stock from 450,000,000 shares to 900,000,000 shares” · word for word

Concentrated ownership and control by Invus

“Invus, L.P. and related parties 204,489,050 — 48.3 %”

Potential for future dilutive equity issuances

“We expect that our future growth may require the use of our common stock from time to time either as consideration for acquisitions or as part of a financing” · word for word

Clinical trial and regulatory risk for pipeline assets

“Dependence on FDA feedback and trial enrollment for sotagliflozin and pilavapadin.”

Significant shareholder control

“Invus, L.P. and its affiliates own a substantial interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.” · word for word

Debt repayment burden

“Aggregate payments of $4.6 million and $54.4 million, including debt principal and final exit fee payments (equal to 7% of the remaining amount funded under the loans), will be due during the fiscal years ended December 31, 2026 and December 31, 2027, respectively.” · word for word

Dependence on clinical trial success

“We depend heavily on our ability to successfully complete the ongoing research and development of our drug programs. If we fail to successfully complete and gain positive results from such research and development efforts, our business will suffer and our stock price will likely decline.” · word for word

Regulatory uncertainty for ZYNQUISTA

“The FDA issued a complete response letter in March 2019 regarding our NDA for ZYNQUISTA in type 1 diabetes and confirmed that position in denying two appeals of the complete response letter in November 2019 and March 2020. The FDA issued an additional complete response letter in December 2024 regarding our NDA for ZYNQUISTA as an adjunct to insulin therapy f” · word for word

Insufficient capital for pilavapadin Phase 3

“We do not have sufficient capital to support Phase 3 development of pilavapadin in DPNP or in neuropathic pain broadly. If we are unable to establish a strategic collaboration or other arrangement for that purpose, our capital needs will be substantially higher and we may be unable to obtain financing sufficient to fund Phase 3 development of pilavapadin on ” · word for word

Massive dilution; Invus entities to hold ~51% post-conversion; potential change of control.

“the Invus Entities will hold approximately 51% of the outstanding Common Stock” · word for word

Significant dilution from proposed public offering and private placement; cash burn rate may require further capital raises.

“Proposed public offering of common stock; concurrent private placement to Invus affiliate; cash $125.2M.”

Milestone payments uncertain; potential $20M additional milestones not guaranteed.

“Potential for up to an additional $20 million in milestone payments throughout 2026 (although there is no certainty such milestones will be reached on the timeline expected or at all).” · word for word

No material risk, administrative correction only.

“Correction of inadvertent statement, no financial impact.”

Dependence on collaborations

“We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our approved drug products.” · word for word

Regulatory risk for sotagliflozin in T1D

“The FDA issued a complete response letter regarding our New Drug Application for sotagliflozin in type 1 diabetes in March 2019 and an additional complete response letter in December 2024.” · word for word

Accumulated deficit

“Since our inception, we have incurred significant losses and, as of September 30, 2025, we had an accumulated deficit of approximately $2.0 billion.” · word for word

Dependence on pipeline success and regulatory approvals for future value.

“Pipeline programs (pilavapadin, LX9851, sotagliflozin) still in development; regulatory feedback pending for Zynquista.”

Limited commercial revenue from INPEFA ($1M) indicates low market penetration.

“INPEFA sales only $1.0 million in Q3 2025.”

Dilution risk from potential equity issuance of up to $75M.

“Company may sell up to $75M in common stock via ATM offering.”